March 2023  

Topical dexamethasone delivery to the retina: An aqueous cyclodextrin-based microsuspension

By Thorsteinn Loftsson and Einar Stefansson. Published by the Journal of Drug Delivery Science and Technology

January 2022  

Topical drug delivery to the retina: obstacles and routes to success

By Thorsteinn Loftsson. Published in Expert Opinion in Drug Delivery

June 2021  

Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure

By Laura Lorenzo-Soler et al. Published in Acta Ophthalmologica

May 2021  

Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits

By Martin Kallab et al. Published in Pharmaceuticals

March 2021  

Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations

By Suppakan Sripetch and Thorsteinn Loftsson. Published by International Journal of Pharmacology

December 2022  

OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study

By Michael Korenfeld et al. Published by Clinical Therapeutics

July 2022  

Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study

By Einar Stefansson et al. Published by Acta Ophthalmologica

Octobre 2021  

Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema

By Masaki Tanito et al. Published in Investigative Ophthalmology & Visual Science (IOVS, an ARVO journal)

August 2015

Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis – a pilot study

By Shiri Shulman et al. Published by Acta Ophthalmologica

July 2015  

Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

By Akihiro Ohira et al. Published by Acta Ophthalmologica

July 2022

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

By Lee Sheetle et al. Published by Clinical Ophthalmology

June 2022

Efficacy and Safety of OCS-02 a novel, potent, topical TNFα antibody in acute anterior uveitis (AAU): a phase 2 study

By Theodore A. Pasquali et al. Published by Translational Vision Science & Technology (TVST)

March 2023

A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis

By Pablo Villoslada et al. Published by Nature in Scientific Reports

July 2019

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation

By Pablo Villoslada et al. Published by Neurotherapeutics